Parkinson Platform Noord Nederland

Around half of all patients with advanced Parkinson's disease will develop hallucinations or delusions. Treatments for Parkinson's disease psychosis are scarce, in part because many antipsychotics are known to worsen motor symptoms, or are not effective. In 2016, pimavanserin became the first antipsychotic to be recommended by the US Food and Drug Administration (FDA) for the treatment of Parkinson's disease psychosis. Since then, there have been numerous reports of serious adverse events, including deaths.